Understanding a Zantac Cancer Lawsuit – Do You Have a Claim?
August 18, 2020
The U.S. Food and Drug Administration (FDA) recently revealed that Zantac and generic varieties could contain a chemical that may be linked to cancer. Lawsuits against Zantac manufacturers allege that the drug contains a cancer-causing chemical called N-Nitrosodimethylamine (NDMA). Patients are advised to stop taking medications containing this harmful chemical. If you believe you have experienced adverse symptoms caused by taking these prescription medications, it’s crucial to speak with a personal injury attorney right away.
What is Zantac?
Zantac is a popular name for an antacid medication called ranitidine that has been on the market in the U.S. since the early 1980s. It is available over the counter or by prescription and is commonly used for heartburn, acid reflux, and other stomach, throat, and gastrointestinal issues.
The Link Between Zantac and Cancer
Zantac is the brand name of a heartburn medication called ranitidine. In April 2020, the FDA announced its request to immediately withdraw all prescription and over-the-counter ranitidine drugs from the market. It was determined that Nitrosodimethylamine (NDMA) in some ranitidine products, when stored at higher than room temperatures, may result in consumer exposure to unacceptable levels of this chemical. The contaminant, NDMA, is a probable human carcinogen and can pose a risk to public health. Significant NDMA exposure could result from taking the brand name or generic ranitidine products, regardless of where they were manufactured.
Types of Cancer
The following cancer types could potentially be caused by previous use of Zantac:
- Non-Hodgkins lymphoma
- Multiple myeloma
If you took Zantac or other generic ranitidine products and developed cancer, you should speak with an experienced personal injury attorney. Potter Burnett Law intends to provide you and your loved ones with the justice and compensation you deserve. Contact us today for a free case evaluation.
Let Our Pride Protect Yours.